Acquired resistance to EGFR tyrosine kinase inhibitors alters the metabolism of human head and neck squamous carcinoma cells and xenograft tumours

• Published in: British journal of cancer Vol. 112; no. 7; pp. 1206 - 1214
• Main Authors: Beloueche-Babari, M, Box, C, Arunan, V, Parkes, H G, Valenti, M, De Haven Brandon, A, Jackson, L E, Eccles, S A, Leach, M O
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 31.03.2015; Nature Publishing Group
• Subjects: 692/699/67/1059/2326; 692/699/67/1536; 692/699/67/1857; 692/699/67/2327; Animals; Biomedical and Life Sciences; Biomedicine; Cancer Research; Carcinoma, Squamous Cell - drug therapy; Carcinoma, Squamous Cell - metabolism; Cell Line, Tumor; Disease Models, Animal; Drug Resistance; Drug Resistance, Neoplasm; Epidemiology; ErbB Receptors - antagonists & inhibitors; Head and Neck Neoplasms - drug therapy; Head and Neck Neoplasms - metabolism; Humans; Mice; Mice, Nude; Molecular Medicine; Oncology; Protein Kinase Inhibitors - pharmacology; Squamous Cell Carcinoma of Head and Neck; Translational Therapeutics; Xenograft Model Antitumor Assays; EGFR tyrosine kinase inhibitors; metabolism; acquired drug resistance; head and neck cancer; biomarkers

Background: Acquired resistance to molecularly targeted therapeutics is a key challenge in personalised cancer medicine, highlighting the need for identifying the underlying mechanisms and early biomarkers of relapse, in order to guide subsequent patient management. Methods: Here we use human head a...